THE EFFECT OF INCREASED HEPCIDIN EXPRESSION ON THE PHARMACOKINETICS OF FERROUS SULFATE IN PATIENTS WITH IRON DEFICIENCY ON THE BACKGROUND OF ANEMIA OF CHRONIC DISEASES
- Autores: Osipyan E.A.1, Makhova A.A.1, Drozdov V.N.1, Shikh E.V.1
-
Afiliações:
- I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University]
- Edição: Volume 8, Nº 4 (2022)
- Páginas: 56-61
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/289002
- DOI: https://doi.org/10.18565/therapy.2022.4.56-61
- ID: 289002
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Currently, the question of how long the level of hepcidin is able to change the metabolism of iron preparations used to compensate for the emerging iron deficiency (ID) is still under consideration. The aim is to study the pharmacokinetics of iron preparations in patients with ID which arised on the background of anemia of chronic diseases (ACD), comparatively with patients with isolated iron deficiency anemia (IIDA). Material and methods. A comparison of pharmacokinetics of iron sulfate in 15 female patients with IIDA and 15 female patients with ID are on the background of ACD was made. Results. The main indicators of iron exchange in the study groups were not significantly different, except for the level of iron-regulating protein hepcidin in patients with ACD + ID comparatively to IIDA patients, 6,1±3,6 versus 15,1±7,3 ng/ml. The area under the curve (AUC) of basal level of iron was 150,96±43,97 pmolxhour/l in patients with IIDA and 112,65±15,88 pmolxhour/l in patients with ACD + ID. After taking 200 mg of iron sulfate AUC increased to 310,18±73,02 pmolxhour/l in patients with IIDA and up to 141,4 pmolxhour/l in patients with ACD + ID. In patients with IIDA, the value of the maximum concentration (Cmax) of iron sulfate in blood (21,2 pmol/l) was achieved more quickly - after 3,1 hours after medicine intake; in patients with ACD and ID Cmax (5,2 pmol/l) was achieved only after 5,6 hours. Conclusion. The obtained data indicate the effect of increased influence of hepcidin at pharmacokinetics of iron preparations in patients with ACD, accompanied by ID.
Texto integral
Sobre autores
Elena Osipyan
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University]
Email: lenaosipyan@gmail.com
postgraduate student of the Department of clinical pharmacology and propaedeutics of internal diseases 119991, Moscow, 8/2 Trubetskaya Str
Anna Makhova
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University]Dr. med. habil., associate professor, associate professor of the Department of clinical pharmacology and propaedeutics of internal diseases 119991, Moscow, 8/2 Trubetskaya Str
Vladimir Drozdov
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University]Dr. med. habil., professor, professor of the Department of clinical pharmacology and propaedeutics of internal diseases 119991, Moscow, 8/2 Trubetskaya Str
Evgenia Shikh
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University]Dr. med. habil., professor, head of the Department of clinical pharmacology and propaedeutics of internal diseases 119991, Moscow, 8/2 Trubetskaya Str
Bibliografia
- Kassebaum N.J., Jasrasaria R., Naghavi M. et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014; 123(5): 615-24. https://dx.doi.org/10.1182/blood-2013-06-508325.
- Nemeth E., Ganz T. Hepcidin and iron-loading anemias. Haematologica. 2006; 91(6): 727-32. https://dx.doi.org/10.3324/%25x.
- Nemeth E., Valore E.V., Territo M. et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101(7): 2461-63. https://dx.doi.org/10.1182/blood-2002-10-3235.
- Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9): 1271-76. https://dx.doi.org/10.1172/JCI20945.
- Nicolas G., Chauvet C., Viatte L. et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110(7): 1037-44. https://dx.doi.org/10.1172/JCI15686.
- Weinstein D.A, Roy C.N., Fleming M.D. et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002; 100(10): 3776-81. https://dx.doi.org/10.1182/blood-2002-04-1260.
- Nicolas G., Viatte L., Lou D.-Q. et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nature Genetics. 2003; 34(1): 97-101. https://dx.doi.org/10.1038/ng1150.
- Arezes J., Nemeth E. Hepcidin and iron disorders: new biology and clinical approaches.Int J Lab Hematol. 2015; 37(Suppl 1): 92-98. https://dx.doi.org/10.1111/ijlh.12358.
- Armitage A. E., Eddowes L.A, Gileadi U. et al. Hepcidin regulation by innate immune and infectious stimuli. Blood. 2011; 118(15): 4129-39. https://dx.doi.org/10.1182/blood-2011-04-351957.
- Левин А.А., Казюкова Т.В., Цветаева Н.В. с соавт. Гепсидин как регулятор гомеостаза железа. Педиатрия. Журнал им. ГН. Сперанского. 2008; 1; 11. [Levina A.A., Kazyukova T.V., Tsvetaeva N.V. et al. Hepsidin as regulator of iron homeostasis. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatrics. Journal named after G.N. Speransky. 2008; 1; 11 (In Russ.)].
- Fleming R.E., Sly W.S. Ferroportin mutation in autosomal dominant hemochromatosis: Loss of function, gain in understanding. J Clin Invest. 2001; 108(4): 521-22. https://dx.doi.org/10.1172/JCI13739.
- Moretti D., Goede J.S., Zeder C. et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twicedaily doses in iron-depleted young women. Blood. 2015; 126(17): 1981-89. https://dx.doi.org/10.1182/blood-2015-05-642223
- Zimmermann M.B., Troesch B., Biebinger R. et al. Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidin. Am J Clin Nutr. 2009; 90(5): 1280-87. https://dx.doi.org/10.3945/ajcn.2009.28129.
- Roe M.A., Collings R., Dainty J.R. et al. Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men. Am J Clin Nutr. 2009; 89(4): 1088-91. https://dx.doi.org/10.3945/ajcn.2008.27297.
Arquivos suplementares
